JP3681480B2 - Composition that masks the unpleasant taste of drugs - Google Patents
Composition that masks the unpleasant taste of drugs Download PDFInfo
- Publication number
- JP3681480B2 JP3681480B2 JP25636396A JP25636396A JP3681480B2 JP 3681480 B2 JP3681480 B2 JP 3681480B2 JP 25636396 A JP25636396 A JP 25636396A JP 25636396 A JP25636396 A JP 25636396A JP 3681480 B2 JP3681480 B2 JP 3681480B2
- Authority
- JP
- Japan
- Prior art keywords
- unpleasant taste
- drug
- formula
- composition
- layered double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Description
【０００１】
【産業上の利用分野】
本発明は、薬物の有する不快な味を隠蔽する組成物に関する。
【０００２】
【発明の背景及び従来技術】
層状複水酸化物は、層間の陰イオンが交換できるというユニークな性質を有しており、各種機能性物質の合成出発物質として最近注目を集めている化合物である。その代表的な化合物であるMg-Al系炭酸型層状複水酸化物である「合成ヒドロタルサイト」は、制酸剤として広く用いられている。
一方、薬物は経口的に投与される場合が多いが、苦味等の不快な味を有する薬物は服用しずらいため、被覆錠剤、カプセル剤等の剤形とすることが多い。しかし、散剤、顆粒剤等の剤形を選択せざるを得ない場合も多く、特に小児や老齢の患者には多大の苦痛を与えている。このため、苦味防止については多くの技術が開発されている。例えば、顆粒剤を水溶性の皮膜によりコーティングする方法、融点４０℃〜１００℃のワックス類を溶融しその中に不快な風味を呈する薬物を分散後固化させて散剤等を得る方法等が知られている。
【０００３】
【発明が解決しようとする課題】
薬物の不快な味を防止するには、薬物の物理化学的な性質や、製造コスト等を考慮して最適な手段を選ぶ必要があり、その選択肢は多い方が望ましい。そのため、薬物の不快な味を防止するための更なる技術が望まれている。
【０００４】
【課題を解決するための手段】
本発明は、不快な味を有する薬物および次式で表される層状複水酸化物から成る薬物の不快な味を隠蔽する組成物である。
【化３】
【０００５】
本発明で使用する層状複水酸化物は、市販されているものを使用することができるし、新たに合成することもできる。例えば、市販されているものとしては、「合成ヒドロタルサイト」（協和化学株式会社）として入手できる。また、「合成ヒドロタルサイト」には、比表面積等その性質に応じて種々のグレードがあるが、本発明ではいずれも用いることができる。
また、新たに合成する場合、例えば一般式
【化４】
【０００６】
４０℃に保った1MのNa2CO3水溶液に1MのMgCl2と1MのFeCl3の混合水溶液をかき混ぜながら滴下して加水分解を行い、次いで７０℃に温度を上げ固体生成物を１時間熟成することにより製造する。この間、2MのNaOH水溶液を滴下することによりｐＨを８〜１１に保持する。固体生成物は固液分離した後、さらに1MのNa2CO3水溶液に添加し、５時間加熱還流することにより再び熟成を行う。固体生成物は十分水洗いした後、アセトンとエーテルで洗浄を行い、６０℃で２４時間減圧乾燥する。熟成とは結晶を成長させることを意味し、熟成時間を変えることにより種々の大きさ、比表面積を有する結晶を得ることができる。
【０００７】
本発明に使用する層状複水酸化物のより好ましいものは次式で表される。
【化５】
【０００８】
本発明に使用される不快な味を有する薬物における不快な味とは、苦味、収斂味、酸味等味覚に不快な刺激を与えることを意味する。不快な味を有する薬物としては、例えば塩酸チクロピジン、塩酸マプロチリン、マレイン酸トリメブチン、臭化水素酸デキストロメトルファン、塩化ベルベリン、ジギトキシン、スルピリン、塩酸アゼラスチン、塩酸エチレフリン、塩酸ジルチアゼム、塩酸プロプラノロール、クロラムフェニコール、アミノフィリン、エリスロマイシン、フェノバルビタール、パントテン酸カルシウム、塩酸インデロキサジン、塩酸アミノグアニジン等を挙げることができる。
【０００９】
本発明にかかる組成物は、例えば次にように製造することができる。不快な味を有する薬物を水に溶解し、層状複水酸化物を添加し、窒素雰囲気下、室温で振盪または攪拌する。その後、濾過して固液分離し、得られた固体を乾燥して本発明にかかる不快な味を隠蔽した組成物を得ることができる。
また、添加する層状複水酸化物をあらかじめ４００℃以上の温度で数時間焼成したものを使用することもできる。
【００１０】
本発明にかかる、不快な味を有する薬物と層状複水酸化物の割合は、薬物の種類により一概にいえないが、一般に層状複水酸化物１重量部に対し、薬物0.001〜2重量部であり、好ましくは0.01〜1重量部、より好ましくは0.01〜0.7重量部である。
本発明に使用される層状複水酸化物の一部は、制酸剤として使用されているものであるため、その安全性は極めて高い。
本発明にかかる組成物はそのままでも、通常使用される賦形剤を用いて錠剤、散剤、顆粒剤等の経口投与用の剤形としてもよい。
【００１１】
【発明の効果】
以下の実施例１〜５で得られた組成物を被験者数人が口に含み試験した結果、薬物そのものよりも著しく不快な味が低減していることが確かめられた。これは薬物が層状複水酸化物の層間に取り込まれるか、表面に吸着することにより、口中において遊離し難くなっているためと考えられる。
【００１２】
【実施例】
実施例１ 塩酸チクロピジン0.3gを蒸留水100mlに溶解しその50mlをとり、式[Ｍg0.75Ａｌ0.25(ＯＨ)2］+0.25［（ＣＯ3）0.125］-0.25・0.69Ｈ2Ｏで表される層状複水酸化物をあらかじめ５００℃で２時間焼成したもの0.2gを添加し、窒素ガス雰囲気下、２５℃で２４時間振盪した。その後、遠心分離により固液分離し、得られた固体生成物を蒸留水で３回洗浄し、６０℃減圧下２４時間乾燥して本発明にかかる組成物を得た。塩酸チクロピジンの含有率は43.1%であった。
【００１３】
実施例２ 塩酸マプロチリン0.74gを蒸留水100mlに溶解しその50mlをとり、式 [Ｍg0.75Ａｌ0.25(ＯＨ)2］+0.25［（ＣＯ3）0.125］-0.25・0.69Ｈ2Ｏで表される層状複水酸化物をあらかじめ４００℃で２時間焼成したもの0.2gを添加し、窒素ガス雰囲気下、２５℃で２４時間振盪した。その後、遠心分離により固液分離し、得られた固体生成物を蒸留水で３回洗浄し、６０℃減圧下２４時間乾燥して本発明にかかる組成物を得た。塩酸マプロチリンの含有率は63.8%であった。
【００１４】
実施例３ マレイン酸トリメブチン0.5gを蒸留水100mlに溶解しその50mlをとり、式[Ｍg0.75Ａｌ0.25(ＯＨ)2］+0.25［（ＣＯ3）0.125］-0.25・0.69Ｈ2Ｏで表される層状複水酸化物を0.2g添加し、窒素ガス雰囲気下、２５℃で１週間振盪した。その後、遠心分離により固液分離し、得られた固体生成物を蒸留水で３回洗浄し、６０℃減圧下２４時間乾燥して本発明にかかる組成物を得た。マレイン酸トリメブチンの含有率は50.9%であった。
【００１５】
実施例４ 臭化水素酸デキストロメルファン0.37gを蒸留水100mlに溶解しその50mlをとり、式[Ｍg0.75Ａｌ0.25(ＯＨ)2］+0.25［（ＣＯ3）0.125］-0.25・0.69Ｈ2Ｏで表される層状複水酸化物をあらかじめ５００℃で１時間焼成したもの0.2gを添加し、窒素ガス雰囲気下、２５℃で２４時間振盪した。その後、遠心分離により固液分離し、得られた固体生成物を蒸留水で３回洗浄し、６０℃減圧下２４時間乾燥して本発明にかかる組成物を得た。臭化水素酸デキストロメルファンの含有率は71.2%であった。
【００１６】
実施例５ 塩酸チクロピジン0.03gを蒸留水100mlに溶解しその50mlをとり、式 [Ｍg0.75Ａｌ0.25(ＯＨ)2］+0.25［（ＣＯ3）0.125］-0.25・0.69Ｈ2Ｏで表される層状複水酸化物をあらかじめ５００℃で２時間焼成したもの0.2gを添加し、窒素ガス雰囲気下、２５℃で２４時間振盪した。その後、遠心分離により固液分離し、得られた固体生成物を蒸留水で３回洗浄し、６０℃減圧下２４時間乾燥して本発明にかかる組成物を得た。塩酸チクロピジンの含有率は6.2%であった。[0001]
[Industrial application fields]
The present invention relates to a composition that masks the unpleasant taste of drugs.
[0002]
BACKGROUND OF THE INVENTION AND PRIOR ART
The layered double hydroxide has a unique property that an anion between layers can be exchanged, and is a compound that has recently attracted attention as a synthetic starting material for various functional substances. “Synthetic hydrotalcite” which is a representative compound of Mg—Al-based carbonate type layered double hydroxide is widely used as an antacid.
On the other hand, drugs are often administered orally, but drugs having an unpleasant taste such as bitterness are difficult to take, and are often in dosage forms such as coated tablets and capsules. However, there are many cases in which a dosage form such as a powder or a granule must be selected, which causes great pain especially for children and elderly patients. For this reason, many techniques have been developed for bitterness prevention. For example, a method of coating a granule with a water-soluble film, a method of melting a wax having a melting point of 40 ° C. to 100 ° C., dispersing a drug exhibiting an unpleasant flavor therein, and solidifying it after dispersion are known. ing.
[0003]
[Problems to be solved by the invention]
In order to prevent an unpleasant taste of a drug, it is necessary to select an optimal means in consideration of the physicochemical properties of the drug, manufacturing costs, and the like, and it is desirable to have many options. Therefore, a further technique for preventing the unpleasant taste of the drug is desired.
[0004]
[Means for Solving the Problems]
The present invention is a composition for masking the unpleasant taste of a drug comprising a drug having an unpleasant taste and a layered double hydroxide represented by the following formula.
[Chemical 3]
[0005]
As the layered double hydroxide used in the present invention, a commercially available one can be used, or it can be newly synthesized. For example, a commercially available product can be obtained as “synthetic hydrotalcite” (Kyowa Chemical Co., Ltd.). “Synthetic hydrotalcite” has various grades such as specific surface area depending on its properties, and any of them can be used in the present invention.
In addition, when newly synthesized, for example, the general formula
[0006]
Hydrolysis is carried out by dropwise addition of 1M MgCl 2 and 1M FeCl 3 to a 1M Na 2 CO 3 aqueous solution kept at 40 ° C., then the temperature is raised to 70 ° C. and the solid product is aged for 1 hour. It is manufactured by doing. During this time, the pH is maintained at 8-11 by dropwise addition of 2M NaOH aqueous solution. After the solid product is separated into solid and liquid, it is further aged by adding it to 1M Na 2 CO 3 aqueous solution and heating to reflux for 5 hours. The solid product is thoroughly washed with water, then washed with acetone and ether, and dried under reduced pressure at 60 ° C. for 24 hours. Aging means growing crystals, and crystals having various sizes and specific surface areas can be obtained by changing the aging time.
[0007]
A more preferable layered double hydroxide used in the present invention is represented by the following formula.
[Chemical formula 5]
[0008]
The unpleasant taste in the drug having an unpleasant taste used in the present invention means giving an unpleasant stimulus to taste such as bitter taste, astringent taste, and sour taste. Drugs with an unpleasant taste include, for example, ticlopidine hydrochloride, maprotiline hydrochloride, trimebutine maleate, dextromethorphan hydrobromide, berberine chloride, digitoxin, sulpiline, azelastine hydrochloride, ethylephrine hydrochloride, diltiazem hydrochloride, propranolol hydrochloride, chloramphenic acid. Cole, aminophylline, erythromycin, phenobarbital, calcium pantothenate, indeloxazine hydrochloride, aminoguanidine hydrochloride and the like can be mentioned.
[0009]
The composition concerning this invention can be manufactured as follows, for example. Dissolve drug with unpleasant taste in water, add layered double hydroxide, shake or stir at room temperature under nitrogen atmosphere. Then, the composition which filtered and solid-liquid-separated and dried the obtained solid and masked the unpleasant taste concerning this invention can be obtained.
Further, it is also possible to use a layered double hydroxide to be added which has been fired for several hours at a temperature of 400 ° C. or higher.
[0010]
The ratio of the drug having an unpleasant taste and the layered double hydroxide according to the present invention cannot be generally specified depending on the kind of the drug, but generally 0.001 to 2 parts by weight of the drug with respect to 1 part by weight of the layered double hydroxide. Yes, preferably 0.01 to 1 part by weight, more preferably 0.01 to 0.7 part by weight.
Since part of the layered double hydroxide used in the present invention is used as an antacid, its safety is extremely high.
The composition according to the present invention may be used as it is, or may be used as a dosage form for oral administration such as tablets, powders, granules and the like using commonly used excipients.
[0011]
【The invention's effect】
As a result of the test in which several subjects included the compositions obtained in Examples 1 to 5 below in their mouths, it was confirmed that the taste unpleasantly reduced compared to the drug itself. This is considered to be because the drug is hardly released in the mouth by being taken in between the layers of the layered double hydroxide or adsorbed on the surface.
[0012]
【Example】
Example 1 0.3 g of ticlopidine hydrochloride was dissolved in 100 ml of distilled water, 50 ml of the solution was taken and expressed by the formula [Mg 0.75 Al 0.25 (OH) 2 ] +0.25 [(CO 3 ) 0.125 ] −0.25 · 0.69 H 2 O 0.2 g of a layered double hydroxide previously calcined at 500 ° C. for 2 hours was added and shaken at 25 ° C. for 24 hours in a nitrogen gas atmosphere. Thereafter, solid-liquid separation was performed by centrifugation, and the obtained solid product was washed three times with distilled water and dried under reduced pressure at 60 ° C. for 24 hours to obtain a composition according to the present invention. The content of ticlopidine hydrochloride was 43.1%.
[0013]
Example 2 0.74 g of maprotiline hydrochloride was dissolved in 100 ml of distilled water, 50 ml of the solution was taken, and the formula [Mg 0.75 Al 0.25 (OH) 2 ] +0.25 [(CO 3 ) 0.125 ] −0.25 · 0.69H 2 O 0.2 g of the layered double hydroxide previously calcined at 400 ° C. for 2 hours was added and shaken at 25 ° C. for 24 hours in a nitrogen gas atmosphere. Thereafter, solid-liquid separation was performed by centrifugation, and the obtained solid product was washed three times with distilled water and dried under reduced pressure at 60 ° C. for 24 hours to obtain a composition according to the present invention. The content of maprotiline hydrochloride was 63.8%.
[0014]
Example 3 0.5 g of trimebutine maleate was dissolved in 100 ml of distilled water and 50 ml thereof was taken and expressed by the formula [Mg 0.75 Al 0.25 (OH) 2 ] +0.25 [(CO 3 ) 0.125 ] −0.25 · 0.69 H 2 O. 0.2 g of the layered double hydroxide was added and shaken at 25 ° C. for 1 week in a nitrogen gas atmosphere. Thereafter, solid-liquid separation was performed by centrifugation, and the obtained solid product was washed with distilled water three times and dried under reduced pressure at 60 ° C. for 24 hours to obtain a composition according to the present invention. The content of trimebutine maleate was 50.9%.
[0015]
Example 4 0.37 g of dextromelphane hydrobromide was dissolved in 100 ml of distilled water, 50 ml of the solution was taken, and the formula [Mg 0.75 Al 0.25 (OH) 2 ] +0.25 [(CO 3 ) 0.125 ] −0.25 · 0.69H 2 0.2 g of a layered double hydroxide represented by O which was previously calcined at 500 ° C. for 1 hour was added and shaken at 25 ° C. for 24 hours in a nitrogen gas atmosphere. Thereafter, solid-liquid separation was performed by centrifugation, and the obtained solid product was washed with distilled water three times and dried under reduced pressure at 60 ° C. for 24 hours to obtain a composition according to the present invention. The content of dextromelphane hydrobromide was 71.2%.
[0016]
Example 5 0.03 g of ticlopidine hydrochloride was dissolved in 100 ml of distilled water, and 50 ml of the solution was taken and expressed by the formula [Mg 0.75 Al 0.25 (OH) 2 ] +0.25 [(CO 3 ) 0.125 ] −0.25 · 0.69 H 2 O 0.2 g of the layered double hydroxide previously calcined at 500 ° C. for 2 hours was added and shaken at 25 ° C. for 24 hours in a nitrogen gas atmosphere. Thereafter, solid-liquid separation was performed by centrifugation, and the obtained solid product was washed with distilled water three times and dried under reduced pressure at 60 ° C. for 24 hours to obtain a composition according to the present invention. The content of ticlopidine hydrochloride was 6.2%.
Claims (7)
［M２＋ １−ｘM３＋ ｘ（OH）2］ｘ＋［Aｎ− ｘ／ｎ・yH2O］ｘ− （式１）
[式中Ｍ２＋はＭｇ２＋、Ｚｎ２＋又はＮｉ２＋を示す。Ｍ３＋は、Ａｌ３＋、Ｆｅ３＋、Ｃｒ３＋又はＣｏ３＋を示す。Ａｎ−は、Ｃｌ−、ＳＯ４ ２−、ＣＯ３ ２−又はＮＯ３ −を示す。ｘは０より大きく０．３３以下の実数、ｙは０より大きい実数、ｎは１以上の整数を示す。]A composition comprising a drug having an unpleasant taste and a layered double hydroxide represented by Formula 1, wherein the drug having an unpleasant taste is taken between layers of the layered double hydroxide, thereby reducing the unpleasant taste of the drug. A composition characterized by concealing.
[M 2+ 1-x M 3+ x (OH) 2] x + [A n- x / n · yH 2 O] x- ( Equation 1)
[ Wherein M 2+ represents Mg 2+ , Zn 2+ or Ni 2+ . M 3+ represents Al 3+ , Fe 3+ , Cr 3+ or Co 3+ . A n- is, Cl -, SO 4 2-, CO 3 2- or NO 3 - shows the. x is a real number greater than 0 and less than or equal to 0.33, y is a real number greater than 0, and n is an integer greater than or equal to 1. ]
［M２＋ １−ｘM３＋ ｘ（OH）2］ｘ＋［Aｎ− ｘ／ｎ・yH2O］ｘ− （式１）
[式中Ｍ２＋はＭｇ２＋、Ｚｎ２＋又はＮｉ２＋を示す。Ｍ３＋は、Ａｌ３＋、Ｆｅ３＋、Ｃｒ３＋又はＣｏ３＋を示す。Ａｎ−は、Ｃｌ−、ＳＯ４ ２−、ＣＯ３ ２−又はＮＯ３ −を示す。ｘは０より大きく０．３３以下の実数、ｙは０より大きい実数、ｎは１以上の整数を示す。]A composition for concealing an unpleasant taste of a drug by adding a layered double hydroxide represented by formula 1 to an aqueous solution containing a drug having an unpleasant taste, stirring and mixing, and separating and drying a precipitate. Production method.
[M 2+ 1-x M 3+ x (OH) 2] x + [A n- x / n · yH 2 O] x- ( Equation 1)
[ Wherein M 2+ represents Mg 2+ , Zn 2+ or Ni 2+ . M 3+ represents Al 3+ , Fe 3+ , Cr 3+ or Co 3+ . A n- is, Cl -, SO 4 2-, CO 3 2- or NO 3 - shows the. x is a real number greater than 0 and less than or equal to 0.33, y is a real number greater than 0, and n is an integer greater than or equal to 1. ]
［M２＋ １−ｘM３＋ ｘ（OH）2］ｘ＋［Aｎ− ｘ／ｎ・yH2O］ｘ− （式１）
[式中Ｍ２＋はＭｇ２＋、Ｚｎ２＋又はＮｉ２＋を示す。Ｍ３＋は、Ａｌ３＋、Ｆｅ３＋、Ｃｒ３＋又はＣｏ３＋を示す。Ａｎ−は、Ｃｌ−、ＳＯ４ ２−、ＣＯ３ ２−又はＮＯ３ −を示す。ｘは０より大きく０．３３以下の実数、ｙは０より大きい実数、ｎは１以上の整数を示す。]To the aqueous solution containing a drug having an unpleasant taste, the layered double hydroxide represented by the formula 1 previously baked at a temperature of 400 ° C. or more for 1 hour or more is added, stirred and mixed, and then the precipitate is separated and dried. A method for producing a composition that conceals the unpleasant taste of a drug.
[M 2+ 1-x M 3+ x (OH) 2] x + [A n- x / n · yH 2 O] x- ( Equation 1)
[ Wherein M 2+ represents Mg 2+ , Zn 2+ or Ni 2+ . M 3+ represents Al 3+ , Fe 3+ , Cr 3+ or Co 3+ . A n- is, Cl -, SO 4 2-, CO 3 2- or NO 3 - shows the. x is a real number greater than 0 and less than or equal to 0.33, y is a real number greater than 0, and n is an integer greater than or equal to 1. ]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25636396A JP3681480B2 (en) | 1996-09-27 | 1996-09-27 | Composition that masks the unpleasant taste of drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25636396A JP3681480B2 (en) | 1996-09-27 | 1996-09-27 | Composition that masks the unpleasant taste of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10101580A JPH10101580A (en) | 1998-04-21 |
| JP3681480B2 true JP3681480B2 (en) | 2005-08-10 |
Family
ID=17291649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25636396A Expired - Fee Related JP3681480B2 (en) | 1996-09-27 | 1996-09-27 | Composition that masks the unpleasant taste of drugs |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3681480B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000046974A (en) * | 1998-12-31 | 2000-07-25 | 윤재승 | Composition for oral administration comprising aceglutamide aluminum and carageenan |
| JP2013053134A (en) * | 2011-08-09 | 2013-03-21 | Taisho Pharmaceutical Co Ltd | Oral preparation |
| GB201217911D0 (en) * | 2012-10-05 | 2012-11-21 | Oxford Pharmascience Ltd | Layered double hydroxides |
| JP6385642B2 (en) * | 2013-02-28 | 2018-09-05 | 小林製薬株式会社 | Composition for internal use |
-
1996
- 1996-09-27 JP JP25636396A patent/JP3681480B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10101580A (en) | 1998-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1899270B1 (en) | Method for producing an iron sulfate-based phosphate adsorbent | |
| JP4584830B2 (en) | Method of producing lanthanum oxycarbonate, composition, method of treatment of mammalian hyperphosphatemia, and method of binding phosphate | |
| TWI335218B (en) | Ferric organic compounds, uses thereof and methods of making same | |
| KR101951857B1 (en) | Nanoparticulate phosphate adsorbent on the basis of maghemite or maghemite/magnetite, production and uses thereof | |
| EP0490920B1 (en) | Pharmaceutical preparation binding with gastric acid | |
| AU5188798A (en) | Pharmaceutical composition for rapid suspension in aqueous media | |
| GB2033225A (en) | Orally administrable tablets | |
| JP3681480B2 (en) | Composition that masks the unpleasant taste of drugs | |
| PL117242B1 (en) | Method for manufacturing synthetic aluminium and magnesium silicatejuminija | |
| JP3770518B2 (en) | Oral drugs concealing bitterness | |
| EA034124B1 (en) | Layered double hydroxides | |
| JPH02262534A (en) | Bismuth-containing composition suitable for treatment and preparation thereof | |
| JPH0310608B2 (en) | ||
| KR101636958B1 (en) | Ursodesoxycholic Acid-Synthetic Hydrotalcite-Eudragit Nanohybrid, Pharmaceutical Composition Containing the Same and Method for Preparing the Same | |
| ES2908336T3 (en) | Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation process thereof | |
| JPH0296526A (en) | Powdery or granular drug preparation | |
| WO2006046560A1 (en) | Propiverine-containing oral particulate preparation and process for producing the same | |
| KR20090007226A (en) | Nano-particles containing calcium and method for preparing the same | |
| US2841526A (en) | Fatty acid-resin adsorption product | |
| JPH10101569A (en) | Antacid | |
| JPH0696536B2 (en) | Internal suspension containing antacid | |
| JPS61130239A (en) | Complex | |
| JP3493496B2 (en) | Specific selective lipid adsorption composition | |
| FI79945B (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA MODIFIERADE LEROR. | |
| CN109311837A (en) | Method for generating maltol Fe composition by ferrous hydroxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050506 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050518 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080527 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100527 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100527 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110527 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120527 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120527 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130527 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |